Skip to main content

Advertisement

SpringerLink
Log in

Relationship between plasma metalloproteinase-9 levels and volume and severity of infarct in patients with acute ischemic stroke

  • Original Article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Matrix metalloproteinases (MMP) constitute an endopeptidase family involved in various physiological and pathological processes. It was demonstrated that plasma MMP-9 level was increased in patients with acute ischemic stroke. In this study, it was investigated whether there was a relationship between the levels of plasma MMP-9 and the severity of stroke and infarct volume in patients with acute ischemic stroke. A total of 32 patients with acute ischemic stroke, (16 males and 16 females) and 30 healthy controls were included in the study. Plasma MMP-9 levels were measured using ELISA method. Computed tomography was performed at 48th hour and infarct volume was calculated using the Cavalieri method. The National Institute of Health Stroke Scale (NIHSS) was checked at baseline, 12, 24, and 48th hour. Plasma MMP-9 levels of the patient group at baseline, 12, 24, and 48th hour were found significantly higher compared to the control group (p < 0.05). An important correlation between MMP-9 levels and the infarct volume was observed at baseline, 12, 24, and 48th hour (p < 0.001). Furthermore, a positive correlation was recorded between plasma MMP-9 levels and NIHSS scores at baseline, 12, 24, and 48th hour (p < 0.001). Plasma MMP-9 levels of those of suffering medium and heavy damages were found significantly higher when compared to those of having slight damage (p < 0.05). A significant relationship was also observed between infarct volumes and neurological deficits (p < 0.05). Plasma MMP-9 levels of the patients at 48th hour were found to be significantly lower in recovered patients compared to those who did not improved or worsened (p < 0.05). A positive correlation was recorded between the infarct volume and infarct progression (p < 0.05). In conclusion, this study showed that plasma MMP-9 level substantially increased during the acute period of ischemic cerebrovascular disease and correlated with the severity of the disease and infarct volume. The definition of the exact role of plasma MMP-9 after ischemic stroke will have important diagnostic implications for stroke and for the development of therapeutic strategies aimed at modulating plasma MMP-9.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Matrisian LM (1990) Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6:121–125

    Article  PubMed  CAS  Google Scholar 

  2. Horstmann S, Kalb P, Koziol J, Gardner H, Wagner S (2003) Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients: influence of different therapies. Stroke 34:2165–2172

    Article  PubMed  Google Scholar 

  3. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ (1995) Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke 26:2120–2126

    Article  PubMed  CAS  Google Scholar 

  4. Montaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, González MA, Monasterio J (2001) Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 32:1759–1766

    Article  PubMed  CAS  Google Scholar 

  5. Montaner J, Alvarez-Sabín J, Molina C, Anglés A, Abilleira S, Arenillas J, Monasterio J (2001) Matrix metalloproteinase (MMP-9) expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 32:2762–2767

    Article  PubMed  CAS  Google Scholar 

  6. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribó M, Quintana M, Alvarez-Sabín J (2003) Matrix metalloproteinase (MMP-9) pre-treatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 107:598–603

    Article  PubMed  CAS  Google Scholar 

  7. Ramos-Fernandez M, Fernanda Bellolio M, Stead LG (2011) Matrix metalloproteinase-9 as a marker for acute ischemic stroke: a systematic review. J Stroke Cerebrovasc Dis Off J Natl Stroke Assoc 20:47–54

    Article  Google Scholar 

  8. Montaner J, Perea-Gainza M, Delgado P et al (2008) Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke 39:2280–2287

    Google Scholar 

  9. DeGraba TJ, Hallenbeck JM, Pettigrew KD, Dutka AJ, Kelly BJ (1999) Progression in acute stroke: value of the initial NIH Stroke Scale score on patient stratification in future trials. Stroke 30:1208–1212

    Article  PubMed  CAS  Google Scholar 

  10. Gundersen HJ, Jensen EB (1987) The efficiency of systematic sampling in stereology and its prediction. J Microsc 147:229–263

    Article  PubMed  CAS  Google Scholar 

  11. Michel RP, Cruz-Orive LM (1988) Application of the Cavalieri principle and vertical sections method to lung. Estimation of volume and pleural surface area. J Microsc 150:117–136

    Article  PubMed  CAS  Google Scholar 

  12. Mun-Bryce S, Rosenberg GA (1998) Matriks metalloproteinases in cerebrovasculer disease (Review). J Cereb Blood Metab 18:1163–1172

    Article  CAS  Google Scholar 

  13. Romanic AM, Write RF, Arteth AJ, Ohlstein EH, Barone FC (1998) Matrix metalloproteinase expression increases after cerebral focal ischemic in rats: inhibition of matrix metalloproteinase-9 reduces infarct size. Stroke 29:1020–1030

    Article  PubMed  CAS  Google Scholar 

  14. Belayev L, Busto R, Zhao W, Ginsberg MD (1996) Quantitative evaluation of blood–brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res 739:88–96

    Article  PubMed  CAS  Google Scholar 

  15. Fujimura M, Gasche Y, Morita-Fujimura Y, Massengale J, Kawase M, Chan PH (1999) Early appearance of activated matrix metalloproteinase-9 and blood–brain barrier disruption in mice after focal cerebral ischemic and reperfusion. Brain Res 842:92–100

    Article  PubMed  CAS  Google Scholar 

  16. Rosenberg GA, Navratil M (1997) Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 48:921–926

    Article  PubMed  CAS  Google Scholar 

  17. Kim SC, Singh M, Huang J et al (1997) Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery 41:642–666

    PubMed  CAS  Google Scholar 

  18. Rosenberg GA, Dencoff JE, Correa N, Reiners M, Ford CC (1996) Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood–brain barrier injury. Neurology 46:1626–1632

    Article  PubMed  CAS  Google Scholar 

  19. Rosell A, Ortega-Aznar A, Alvarez-Sabin J et al (2006) İncreased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke 37:1399–1406

    Article  PubMed  CAS  Google Scholar 

  20. Lee SR, Tsuji K, Lo EH (2004) Role of matrix metalloproteinases in delayed neuronal damage after transient global cerebral ischemia. J Neurosci 24:671–678

    Article  PubMed  CAS  Google Scholar 

  21. Asahi M, Wang X, Mori T, Sumii T, Jung JC, Moskowitz MA (2001) Effect of matrix metalloproteinase-9 gene knock-out on the proteolysis of blood–brain barrier and white matter components after cerebral ischemia. J Neurosci 21:7724–7732

    PubMed  CAS  Google Scholar 

  22. Rosell A, Alvarez-Sabin J, Arenillas JF, Rovira A, Delgado P, Fernandez-Cadenas I (2005) A matrix metalloproteinase proteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 36:1415–1420

    Article  PubMed  CAS  Google Scholar 

  23. Montaner J, Rovira A, Molina CA, Arenillas JF, Ribo M, Chacon P (2003) Plasmatic level of neuroinflammatory markers predict the extent of diffusion-weighted image lesions in hyperacute stroke. J Cereb Blood Flow Metab 23:1403–1407

    Article  PubMed  CAS  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Neurology, Medical School of Ataturk University, Erzurum, Turkey

    Recep Demir, Hızır Ulvi, Lütfi Özel, Gökhan Özdemir & Recep Aygül

  2. Department of Neurology, Romatem Hospital, Samsun, Turkey

    Metin Güzelcik

Authors
  1. Recep Demir
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hızır Ulvi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lütfi Özel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gökhan Özdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Metin Güzelcik
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Recep Aygül
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Recep Demir.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Demir, R., Ulvi, H., Özel, L. et al. Relationship between plasma metalloproteinase-9 levels and volume and severity of infarct in patients with acute ischemic stroke. Acta Neurol Belg 112, 351–356 (2012). https://doi.org/10.1007/s13760-012-0067-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-012-0067-4

Keywords

Search

Navigation